17 assets in Kidney Neoplasm

Therapeutic assets addressing Kidney Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Axitinib Kidney Neoplasm	Pfizer	P3	BB (69)
Ipilimumab Kidney Neoplasm	Pfizer	P4	BB (68)
Volitinib Kidney Neoplasm	AstraZeneca	P3	B (60)
NKT2152 Kidney Neoplasm	NiKang Therapeutics, Inc.	P2	B (57)
[18f]rccb6 Kidney Neoplasm	RenJi Hospital	P2	CCC (53)
Hydromorphon Kidney Neoplasm	University of Miami	P2	CCC (53)
Ibuprofen Kidney Neoplasm	University of Miami	P2	CCC (53)
Ketorolac Kidney Neoplasm	University of Miami	P2	CCC (53)
Oxycodone Kidney Neoplasm	University of Miami	P2	CCC (53)
Palbociclib Kidney Neoplasm	NiKang Therapeutics, Inc.	P2	CCC (53)
Perflutren Lipid Microsphere Intravenous Suspension Kidney Neoplasm	UNC Lineberger Comprehensive Cancer Center	P2	CCC (53)
Atezolizumab Kidney Neoplasm	Cancer Research UK	P1/2	CCC (52)
[177lu]lu-dpi-4452 Kidney Neoplasm	ITM Oncologics GmbH	P1/2	CCC (48)
[68ga]ga-dpi-4452 Kidney Neoplasm	ITM Oncologics GmbH	P1/2	CCC (48)
htl0039732 capsules Kidney Neoplasm	Cancer Research UK	P1/2	CC (47)
pf-08634404 Kidney Neoplasm	Pfizer	P1/2	CC (47)
Sasanlimab Kidney Neoplasm	NiKang Therapeutics, Inc.	P2	C (34)